[Clinical study of meproscillarin rates of inactivation and persistence, bioavailability and maintenance dose].
With a rate of inactivation of about 40% and a bioavailability of about 70% corresponding approximately to that of digoxin 14-hydroxy-3beta-[(4-O-methyl-alpha-L-rhamnopyranosyl)oxy]-14beta-bufa-4,20,22-trienolide (meproscillarin, Clift) is--according to our results--a new therapeutic possibility for cardiac decompensated patients, especially in the presence of renal failure. The number of side effects was low. Occasionally diarrhoea occurred which, however, only in a few cases required treatment or discontinuance of therapy.
D000368:Aged; D001682:Biological Availability; D002301:Cardiac Glycosides / Q000008:administration & dosage / Q000009:adverse effects / Q000378:metabolism*; D006331:Heart Diseases / Q000378:metabolism; D006801:Humans; D007408:Intestinal Absorption; D007676:Kidney Failure, Chronic / Q000378:metabolism
D002301:Cardiac Glycosides
Klinische Prüfung von Meproscillarin im Hinblick auf Abkling- und Persistenzquote, Bioverfügbarkeit und Erhaltungsdosis.